Efficacy and safety of R-GemOx regimen for relapsed refractory B-cell lymphoma:a single-arm Meta analysis
Guo-Xin HUANG
Qi-Long CAO
Jian-Zhou TIAN
Jin-Wei AI
Gao-Jing QU
Bin PEI
Abstract：Objective Systematic evaluation of the efficacy and safety of the Rituximab plus gemcitabine and oxaliplatin(R-GemOx)regimen for the treatment of relapsed refractory B-cell lymphoma.Methods The PubMed,Embase,CNKI,CBM,VIP and Wan-Fang databases were systematically searched for experimental and observational studies on the R-GemOx regimen for relapsed refractory B-cell lymphoma.The search time frame is from the establishment of each database to September 13,2022.After extracting the literature and evaluating the quality of the literature in parallel,Meta-analysis was performed using R(4.2.1)software.Results A total of 526 cases of relapsed refractory B-cell lymphoma were included in 13 studies.Meta-analysis showed that the complete response rate(CRR)was 37.48%[95%CI(30.25%,46.45%)];partial response rate(PRR)was 28.62%[95%CI(21.06%,38.90%)];stable disease rate(SDR)was 12.03%[95%CI(7.03%,17.93%)];progressive disease rate(PDR)was 21.20%[95%CI(15.73%,27.22%)];over response rate(ORR)was 62.19%[95%CI(52.25%,74.02%)];clinical benefit rate(CBR)was 79.40%[95%CI(72.49%,85.62%)].Safety was dominated by hematological system toxicity,digestive system toxicity and nervous system toxicity.Conclusion The R-GemOx regimen for relapsed refractory B-cell lymphoma is an effective treatment option with tolerable drug toxicity.
Keywords：R-GemOxRelapsed refractory B-cell lymphomaSingle-arm Meta analysisEfficacySafety
Publication Date：2023-12-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：12( 438-449 )